Feng-Che Kuan

547 total citations
11 papers, 438 citations indexed

About

Feng-Che Kuan is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Feng-Che Kuan has authored 11 papers receiving a total of 438 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 3 papers in Pulmonary and Respiratory Medicine and 2 papers in Molecular Biology. Recurrent topics in Feng-Che Kuan's work include Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Feng-Che Kuan is often cited by papers focused on Colorectal Cancer Treatments and Studies (4 papers), Cancer Treatment and Pharmacology (3 papers) and Hepatocellular Carcinoma Treatment and Prognosis (2 papers). Feng-Che Kuan collaborates with scholars based in Taiwan, United States and France. Feng-Che Kuan's co-authors include Kuan‐Der Lee, Miao-Fen Chen, Min-Chi Chen, Tzu‐Chen Yen, Wen‐Cheng Chen, Ming‐Shian Lu, Paul-Yang Lin, Chung‐Sheng Shi, Liang‐Tseng Kuo and Cheng‐Ta Yang and has published in prestigious journals such as International Journal of Molecular Sciences, British Journal of Cancer and Oncotarget.

In The Last Decade

Feng-Che Kuan

11 papers receiving 432 citations

Peers

Feng-Che Kuan
Jietao Lin China
Wei Xue China
Tomohiro Kubo Japan
Guohong Li China
Lizhu Han China
Krisha Desai United States
Qiang Yan China
Tomáš Hanuš Czechia
Jietao Lin China
Feng-Che Kuan
Citations per year, relative to Feng-Che Kuan Feng-Che Kuan (= 1×) peers Jietao Lin

Countries citing papers authored by Feng-Che Kuan

Since Specialization
Citations

This map shows the geographic impact of Feng-Che Kuan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Feng-Che Kuan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Feng-Che Kuan more than expected).

Fields of papers citing papers by Feng-Che Kuan

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Feng-Che Kuan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Feng-Che Kuan. The network helps show where Feng-Che Kuan may publish in the future.

Co-authorship network of co-authors of Feng-Che Kuan

This figure shows the co-authorship network connecting the top 25 collaborators of Feng-Che Kuan. A scholar is included among the top collaborators of Feng-Che Kuan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Feng-Che Kuan. Feng-Che Kuan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

11 of 11 papers shown
1.
Yeh, Kun‐Huei, Tsai‐Sheng Yang, Tzu‐Chi Hsu, et al.. (2021). Real-world evidence of the safety and effectiveness of regorafenib in Taiwanese patients with metastatic colorectal cancer: CORRELATE Taiwan. Journal of the Formosan Medical Association. 120(11). 2023–2031. 9 indexed citations
2.
Loupakis, Fotios, Lorenzo Antonuzzo, Jean‐Baptiste Bachet, et al.. (2020). Practical considerations in the use of regorafenib in metastatic colorectal cancer. Therapeutic Advances in Medical Oncology. 12. 3863571902–3863571902. 22 indexed citations
3.
Hsu, Hung‐Chih, Wen-Chi Chou, Feng-Che Kuan, et al.. (2018). A Phase II study of S-1 plus oral leucovorin in heavily treated metastatic colorectal cancer patients. Cancer Management and Research. Volume 10. 6061–6070. 2 indexed citations
4.
Wu, Meng–Huang, Ching‐Yu Lee, Tsung‐Jen Huang, et al.. (2018). MLN4924, a Protein Neddylation Inhibitor, Suppresses the Growth of Human Chondrosarcoma through Inhibiting Cell Proliferation and Inducing Endoplasmic Reticulum Stress-Related Apoptosis. International Journal of Molecular Sciences. 20(1). 72–72. 48 indexed citations
5.
Wu, Ching-Yuan, Jong‐Yuh Cherng, Yao‐Hsu Yang, et al.. (2017). Danshen improves survival of patients with advanced lung cancer and targeting the relationship between macrophages and lung cancer cells. Oncotarget. 8(53). 90925–90947. 32 indexed citations
6.
7.
Huang, Cih‐En, Feng-Che Kuan, Kuan‐Der Lee, et al.. (2016). Thrombopoietic cytokines in patients with hepatitis C virus-associated immune thrombocytopenia. Hematology. 22(1). 54–60. 5 indexed citations
8.
Chen, Min-Chi, et al.. (2015). Incidence and risk factors for central venous access port-related infection in Chinese cancer patients. Journal of the Formosan Medical Association. 114(11). 1055–1060. 27 indexed citations
9.
Kuan, Feng-Che, Liang‐Tseng Kuo, Min-Chi Chen, et al.. (2015). Overall survival benefits of first-line EGFR tyrosine kinase inhibitors in EGFR-mutated non-small-cell lung cancers: a systematic review and meta-analysis. British Journal of Cancer. 113(10). 1519–1528. 80 indexed citations
10.
Chen, Miao-Fen, Feng-Che Kuan, Tzu‐Chen Yen, et al.. (2014). IL-6-stimulated CD11b+CD14+HLA-DR− myeloid-derived suppressor cells, are associated with progression and poor prognosis in squamous cell carcinoma of the esophagus. Oncotarget. 5(18). 8716–8728. 130 indexed citations
11.
Lu, Chang-Hsien, Kuan‐Der Lee, Chih‐Cheng Chen, et al.. (2013). Second primary malignancies following thyroid cancer: a population-based study in Taiwan. European Journal of Endocrinology. 169(5). 577–585. 40 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Jietao Lin Breakdown of academic impact, for papers by Wei Xue Breakdown of academic impact, for papers by Tomohiro Kubo Breakdown of academic impact, for papers by Guohong Li Breakdown of academic impact, for papers by Lizhu Han Breakdown of academic impact, for papers by Krisha Desai Breakdown of academic impact, for papers by Qiang Yan Breakdown of academic impact, for papers by Tomáš Hanuš
Rankless by CCL
2026